All In Biotech

Drug Trial Radar · NCT01254604

Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)

A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or Ocular Hypertension in India

Last checked: Nov 20, 2026Latest source record: Sep 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Dec 1, 2011

Primary completion

May 9, 2013

Study completion May 9, 2013

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 6, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of therapy in participants with open-angle glaucoma or ocular hypertension.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • Preservative-Free Tafluprost or vehicleDrug

    Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)

  • Preservative-Free Timolol maleateDrug

    Preservative-free timolol maleate (0.5%) ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Diurnal IOP Change From Baseline at Week 4 - Study EyeTime frame: Baseline and Week 4
  2. Number of Participants With an Adverse Event (AE)Time frame: Up to 14 days after Week 4 visit
  3. Number of Participants Who Discontinued Study Drug Due to an AETime frame: Up to Week 4

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.